Clinical Trial Update: A Study to Learn About Abrocitinib in Adult Patients With Moderate to Severe Atopic Dermatitis.

View source ↗

Summary

Pfizer is conducting a clinical study to evaluate abrocitinib in adults with moderate to severe atopic dermatitis, and the trial is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• Abrocitinib (abrocitinib)

Snippet

Sponsor: Pfizer | Conditions: Atopic Dermatitis, Eczema | Status: RECRUITING